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Abstract: Spasticity is characterized by velocity-dependent increase in tonic stretch reflexes 
and tendon jerks. Many people affected by spasticity receive late treatment, or no treatment, 
which greatly reduces the potential to regain full motor control and restore function. There is 
much to consider before determining treatment for people with spasticity. Treatment of pedi-
atric patients increases the complexity, because of the substantial difference between adult and 
pediatric spasticity. Proper patient evaluation, utilization of scales and measures, and obtaining 
patient and caregiver history is vital in determining optimal spasticity treatment. Further, taking 
into consideration the limitations and desires of individuals serve as a guide to best management. 
We have grouped contributing factors into the IDAHO Criteria to elucidate a multidisciplinary 
approach, which considers a person’s complete field of experience. This model is applied to 
goal setting, and recognizes the importance of a spasticity management team, comprising the 
treatment subject, his/her family, the environment, and a supportive, well-informed medical 
staff. The criteria take into account the complexity associated with diagnosing and treating 
spasticity, with the ultimate goal of improved function.
Keywords: spasticity treatment modalities, pediatric spasticity management, optimal 
management for spasticity
Introduction
Spasticity is clinically described as a motor disorder, characterized by a velocity-
dependent increase in tonic stretch reflexes and exaggerated tendon jerks, resulting 
from hyper-excitability of the stretch reflex, as one component of the upper motor 
neuron syndrome. Many diseases and injuries affecting the central nervous system 
(CNS) result in impairment of neuromuscular function, manifested as spasticity. 
Cerebral palsy (CP), multiple sclerosis (MS), traumatic brain injury (TBI), spinal cord 
injury (SCI), and cerebrovascular accident (CVA) are commonly encountered condi-
tions that result in this neuromuscular dysfunction. In people with spasticity, neural 
impulses misfire, resulting in symptomatology that can affect both the upper and 
lower extremities.
An estimated 500,000 people in the United States, and twelve million people 
worldwide, experience spasticity.1 Yet, many of those affected are neglected, or treated 
late for their spasticity, and relegated to salvage treatment of end effects on the mus-
culoskeletal system. This approach leaves little hope for regaining full motor control 
and restoring pre-disease or pre-injury function.
When treating spasticity, it is imperative to understand its functional effects, and 
recognize that spasticity is not always deemed detrimental by the affected person, 
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or their caregiver. In its mildest form, spasticity may substitute 
for muscular weakness, aid in the preservation of muscle mass, 
and decrease the prevalence of deep venous thrombosis.2 
However, spasticity is damaging in its more severe forms. 
Spasticity causes imbalanced muscle forces that act upon bones, 
joints, and the muscles themselves. This imbalance results in 
bony angular and torsional deformities, subluxation/dislocation 
of joints, capsular contractions, and muscle shortening. These 
findings were substantiated by Mercer Rang, who studied 
spastic mice that had developed restricted joint range, restrictive 
muscle excursion, and bony degeneration.3 These findings 
are considered to be the musculoskeletal ramifications of 
spasticity. Other skeletal ramifications include pain, casting 
or bracing challenges, skin complications, and challenges 
for fracture management.4 Additionally, spasticity impacts 
children differently than adults. Spasticity during growth 
compounds the soft tissue ramifications of increased tone. This 
is highlighted by excessive muscle shortening and abnormal 
bone growth, as a result of the imbalanced muscle forces acting 
upon growth plates.5,6
Many aspects are considered before deciding on treat-
ment options for individuals with spasticity. These aspects 
not only include present-time quality of life, comfort, and 
function, but also future impairments, which may present 
as the result of growth, or expected decline in strength with 
age. Assessment of these aspects includes the patient’s and 
the caregiver’s perspectives.7
Patient evaluation
While it is easily recognized that severe TBI, CVA, and a 
variety of neurological disorders can result in spasticity, 
the actual diagnosis of spasticity is more complex. The 
complexity arises from challenges in distinguishing among 
abnormal patterns of muscle tone, such as volitional guard-
ing, contracture, dystonia, paresis, paratonia, and rigidity.4,8–10 
Furthermore, other movement disorders may be present in 
addition to spasticity. The incidence of these other movement 
disorders varies, depending upon the underlying etiology. It 
can be very frequent in cerebral palsy, rare following stroke 
(3.7%), and nonexistent following spinal cord injury.11 
Establishing the presence of accompanying movement 
abnormalities is important, as many of these are unaffected 
by traditional treatments for spasticity, and may appear more 
prominent when spasticity is reduced. Observation of the 
patient during tasks, and in ambulation, can identify these 
additional movement disorders by their salient features.12
Video analysis is extremely helpful in diagnosis, and 
serves as a useful aid in detecting change following treatment. 
Though formal motion analysis in a gait lab is ideal, 
observational analysis with simple video is inexpensive, less 
labor- and time-intensive, and is often equally informative. 
We highly recommend obtaining video during an initial, 
thorough baseline physical therapy visit, when possible. 
Many picture archiving and communicating systems store 
these videos alongside radiographic studies, making them 
readily accessible.
During these initial sessions, passive range of motion 
is assessed during different velocities of movement to 
measure contracture and degree of spasticity. The Modified 
Ashworth Scale (MAS) is the most-utilized scale to measure 
spasticity. Since its inception, however, the validity and 
reliability of MAS has been challenged. To address issues 
with MAS, the Modified Modified Ashworth Scale (MMAS) 
was developed. In the revised scale, the ambiguity of the 
1+ grade has been omitted, and grade 2 has been redefined. 
MMAS ranges from 0–4: 0 = no increase in muscle tone; 
1 = slight increase in muscle tone, manifested by a catch 
and release, or by minimal resistance at the end of the range 
of motion when the affected part(s) is moved in flexion or 
extension; 2 = marked increase in muscle tone, manifested 
by a catch in the middle range and resistance throughout the 
remainder of the range of motion, but the affected part(s) is 
easily moved; 3 = considerable increase in muscle tone, with 
passive movement being difficult; and 4 = affected part(s) 
is rigid in flexion or extension.12 Though MMAS is not cur-
rently widely used, studies have supported the reliability of 
the scale.13 It allows grades to be more clearly defined, and 
provides for better clinical practice.
If appropriate, active motion is assessed for measures 
of function, timed functional trials, fatigability and repeat-
ability, and selective motor control. A number of scales 
exist, which are used with the appropriate diagnoses and 
underlying impairment.14
Though physical examination is a critical component of 
patient evaluation, the patient and caregiver history is also 
integral to determining optimal treatment for spasticity. 
Understanding the limitations that each person experiences 
as a result of the spasticity, as well as understanding their 
respective desire for tone reduction and strengthening, helps 
guide best management. For example, with adults who rely 
upon stand-pivot transfers, and depend upon their spasticity 
to achieve this task, and who have either a low desire or an 
inability to strengthen adequately, intrathecal baclofen may 
not be the optimal choice to reduce spasticity. On the other 
hand, a very motivated young child, with substantial growth 
remaining, and a supportive family, may be an excellent 
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candidate for intrathecal baclofen treatment, despite a pos-
sible temporary early reduction in function.
Treatment options
Two primary treatment algorithms exist for spasticity man-
agement, each dependent upon the magnitude of cognitive 
impairment. The ultimate treatment goal in the first group is 
to improve care and comfort for those who are significantly 
impaired, both physically and mentally, and who reply 
upon others for care. Functional improvement becomes 
increasingly challenging as cognitive ability declines, 
while improving comfort greatly improves quality of life 
for both the impacted individual and their caregiver. Most 
families and caregivers are satisfied with improved comfort, 
increased quality of life, and eased caregiving as outcomes of 
this treatment. The benefits of such an approach are widely 
documented in the literature.15
For the population who are physically debilitated but 
who have lesser degrees of mental impairment, the roles of 
spasticity reduction become less clear. The controversies 
include:
1. Weighing spasticity reduction against potential loss of 
function
2. Spasticity reduction without an associated improvement 
in function.
A common belief is that spasticity reduction options that 
impact on function should be avoided. This phenomenon is 
commonly seen in young individuals with spastic diplegic 
cerebral palsy, and in adult stroke or incomplete spinal cord-
injured patients who live independently. For example, 
caregivers and family members who witness an initial loss 
of ambulation or transfer ability following an intrathecal 
baclofen trial will often deem it a failure. Though this snap-
shot of function may be accurate, ignoring the implications 
of long-term spasticity may be nearsighted. Though spasticity 
may aid in short term preservation of function, it commonly 
results in long-term musculoskeletal impairments, such as 
joint contractures, muscle shortening, and bony deformity. 
Oftentimes, pediatric patients who substitute for weakness 
with spasticity will ultimately lose any function gained 
from utilizing their increased tone, as their mass increases.16 
Therefore, it is important to consider the long-term implica-
tions of spasticity, and to weigh it against short-term gains, 
to avoid this outcome.
Another controversial issue centers on the prevailing 
historical view that spasticity management should lead to 
measurable and immediate improved function in order to 
be considered an effective treatment. Though it is clearly a 
desirable outcome, there are many other elements that affect 
function, making this short- to mid-term goal impossible to 
assess. Currently-used scales perform well in measuring dif-
ferent abilities directly or indirectly impacted by increased 
tone, but do not address the aforementioned aspects, which 
contribute to functional goal attainment, alongside inherent 
ability. For example, the Gross Motor Function Classification 
System (GMFCS) is an excellent classification of mobility 
and ambulatory ability. The GMFCS and similar scales sim-
ply describe categories in which the individual resides.17 As 
a result, these scales limit assessment of potential through 
not taking into account individuals’ characteristics and their 
environmental support.
In response to the limitations of predicting outcomes 
using current classification systems, assessment tools, and 
scales, we devised a concise collection of a small number 
of variables, which we have found to influence function 
in individuals experiencing spasticity, and developed the 
IDAHO Criteria (Figure 1). It is similar in concept to the 
World Health Organization’s International Classification 
of Functioning, Disability and Health (ICF),18 which is 
formidable and rarely used clinically or otherwise.19 The 
ICF is exhaustively detailed in compiling factors to measure 
health and disability, and serves as a valuable research tool. 
The IDAHO Criteria offers a simple alternative schematic 
to assist in evaluating an individual’s potential. This model 
guides goal setting, and recognizes the importance of 
many factors integral to attaining functional improvement; 
treatment options are evaluated holistically for optimal 
outcomes. Approaches that consider the processes involved 
with health care delivery have demonstrated improved patient 
and family satisfaction.20,21
Desire
Infrastructure
Opportunity
Hospital
access
Ability
Figure 1 The IDAHO criteria.
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First, we assess the individual’s Infrastructure (I), which 
is the supportive environment in which they live. Spastic 
individuals who have full-time emotional and physical sup-
port have a distinct advantage. Access to essential exercise 
equipment and the opportunity to learn proper muscle-
strengthening techniques are optimal for improving muscle 
strength and subsequent function.
Next, we assess the individual’s Desire (D), which per-
tains to their motivation and courage in generation and pursuit 
of stated outcomes. Desire is an especially vital component, 
which must be properly addressed in order to confirm that 
the person, his/her family members, and medical staff are 
all fully aware of the person’s situation, thereby permitting 
open communication and establishing realistic goals. It is 
imperative to define Desire because, frequently, the person 
and his/her family members, prior to consultation with the 
physician, may set unreasonable goals regarding spasticity 
management; when these exalted goals are not achieved as 
imagined, discouragement may develop, and impede the 
recovery progress.4 However, through effective communica-
tion and establishing practical, realistic goals, improvement 
can be facilitated. Appropriately addressing the Desire com-
ponent can help to avoid discouragement, and regression in 
recovery can be avoided.
Ability (A) refers to an individual’s inherent physical 
and mental characteristics. This is based on both the level of 
impairment and the pre-existing physical state. For example, 
irrespective of the severity of spasticity, a person with cogni-
tive impairment cannot be assumed to have the same ability to 
improve as a person without deficits. Additionally, selective 
motor control greatly enhances one’s ability to strengthen, 
following spasticity reduction.
Hospital Access (H) is defined by proximity of the 
subject’s residence to professional care services. Hospital 
access demonstrates the existence of geographic disparities, 
in which location is a leading determinant in whether or 
not health care is accessible, along with the ease of access. 
Statistics indicate that, in the United States, a quarter of 
Hispanics, and a third of African-Americans and American 
Indian/Alaskan natives live outside metropolitan areas where 
suitable hospitals are located. Consequentially, a large pro-
portion of people do not receive adequate attention and appro-
priate care, solely due to their location.22 Similarly, in Third 
World countries, access to state-of-the-art care is limited. The 
Hospital Access component of the criteria encourages the 
recognition of location, and the importance of understanding 
that location has a significant impact, not only on the person’s 
treatment plans but also on proper diagnosis.
Finally, Opportunity (O) signifies the economic aspect of 
access to specialty care and treatment opportunities, which has 
the potential to drastically change the treatment directive.23 
Research has revealed that ethnic and racial minorities are 
statistically shown to have incomes that fall below 200 percent 
of the federal poverty level, suggesting that they are more 
likely to be uninsured, in comparison to other Americans. 
Undoubtedly, this implies that a tremendous disparity in 
health care delivery is associated with socioeconomic status, 
which must be recognized when performing evaluations.22
Unfortunately, because of health care disparities, those 
affected by socioeconomic and geographic disparities are also 
affected by disparities in opportunity. Based on their low-
income status, some people are unable to access specialized 
physicians at high-quality hospitals. For this reason, their 
goals and their treatment routes may not be suitable. Thus, 
proper improvement may not be achieved.22
Treatment options are based on the determination of 
localized or generalized spasticity, its level of severity, degree 
of selective motor control, cognitive function, and the per-
sonal needs of the individual. Once these factors have been 
analyzed, different modalities of treatment are considered, 
including nonpharmaceutical, oral medication, intramuscular 
injection, and intrathecal medication.
Nonpharmaceutical methods, which have been utilized 
for many decades to manage spasticity, include bracing, 
casting, occupational therapy, physiotherapy, and surgery. 
Although these methods fail to eliminate the underlying 
issue, they do provide support, substitute for weak muscles, 
and maintain a range of joint motion, in order to alleviate 
the challenges of daily activity.24 While nonpharmaceutical 
and nonsurgical options may aid individuals in mobility, the 
extent to which they are considered successful in improving 
range of motion remains debated. Soft tissue surgical inter-
ventions are utilized as well. But surgery does not directly 
address spasticity. Surgery should be considered a salvage 
method, to optimize outcomes once spasticity has been 
adequately treated. This is particularly true in the pediatric 
population, wherein repeated lengthening of the musculo-
tendinous unit in a growing child often results in weakening 
of muscle. Furthermore, it is the experience of the author 
that outcomes achieved by surgery, regardless of the age 
when performed, are best maintained by optimal spasticity 
management. Selective dorsal rhizotomy (SDR) is another 
surgical option for spasticity management. Historically, it 
has been reserved for children with spastic diplegia who 
have very good strength. A few studies have demonstrated 
good long-term outcomes with this method. The challenge in 
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this conclusion is that children with a degree of underlying 
ability do well regardless of the management chosen.25–27 In 
addition, this surgery is irreversible. Spasticity often returns 
with maturity, and secondary deformities occur.28
Traditionally, orally-administered medications have 
been the primary and most widely used method of treat-
ment for spasticity. Some commonly used oral medications 
include gamma amino butyric acid (GABA) agonists (such 
as baclofen and benzodiazepines) and muscle relaxants 
(such as dantrolene and α2-adrenergic agonists, including 
tizanidine).4,24 Unfortunately, these medications permit short-
term benefits but frequently lead to further complications. 
In cases of severe spasticity, oral medications reduce tone 
inadequately; the tone reduction achieved fluctuates and does 
not provide a steady state of effect.4
Furthermore, the sedating effects of the oral baclofen 
dosages required to provide adequate spasticity manage-
ment commonly interfere with cognitive function and 
development.29 In addition to drowsiness, the systemic side 
effects of dantrolene and tizanidine must be closely moni-
tored, to avoid hematologic and hepatic damage.
Investigations of focal spasticity have shown that local-
ized interventions are a more successful method of treatment. 
Intramuscular injections, which include injections of botu-
linum toxin, alcohol, and phenol have shown to be more 
effective in directly treating the spastic muscle and decreasing 
adverse side effects.4
Botulinum toxin is a natural toxin formed from 
Clostridium botlinum bacteria. It acts by inhibiting the 
release of acetylcholine at the neuromuscular junction, with 
high specificity, and has been demonstrated to be safe and 
efficacious in treating abnormally increased muscle tone.30,31 
Botulinum toxin takes effect two to three days after injection, 
and peaks clinically at 4–6 weeks, gradually wearing off 
at 3–4 months. This leads to staggered results. Those who 
receive the maximum number of injections are relieved, for 
various episodes, approximately 4 months out of a year.32 
However, in patients with good selective motor control, the 
positive results can persist for 6 months or longer. Individuals 
with selective motor control of the antagonistic muscles are 
ideal candidates for botulinum toxin injections.
Alcohol  and  pheno l  a re  bo th  nonse lec t ive 
chemodenervating therapeutic agents, and are less diffusive 
than botulinum toxin. They are less costly options, and are 
advantageous in their rapid onset and localized potency, but 
pose possible risks of soft tissue fibrosis development, as 
well as dysesthesia.33 Also, alcohol and phenol are difficult 
to inject, requiring perineural placement, or placement near 
the point of motor innervation.23 The effects of phenol are 
irreversible, and may reduce contraction during voluntary 
movements, produce scarring, granuloma formation, and 
edema.24 Additionally, given the shorter duration of effect of 
alcohol injections, they are less commonly employed.
Finally, intrathecal baclofen (ITB), approved by the 
Food and Drug Administration in 1996, is being used to 
treat spasticity. Instead of paralyzing muscle cells, ITB 
works as a GABA agonist. GABA is an inhibitory neu-
rotransmitter, which relaxes antagonist muscles (ie, reduces 
co-contraction). Baclofen acts to stimulate GABA receptors, 
directly effecting muscle tone and spasticity. Oral baclofen 
crosses the blood–brain barrier poorly, preventing its effec-
tive entrance into the CNS. When delivered intrathecally, its 
cerebrospinal fluid concentrations are a hundredfold greater 
than those obtained by oral ingestion. Intrathecal baclofen 
has fewer systemic side effects compared to oral baclofen. 
However, the procedure does include additional surgical risks 
and possible complications.34 Evidence supports the efficacy 
of ITB, and indicates greatest efficacy in people with severe 
spasticity. ITB helps to reduce pain, improve sleep, improve 
daily living activities, improve abilities, and enhance quality 
of life.15 ITB is now a commonly practiced therapy, which 
reduces spasticity in people who have CP, and has been proven 
effective by multiple studies.35
Treatment practices
After agreeing on treatment goals with the person and care-
givers involved, the use of our treatment algorithm is based 
upon the degree of body involvement and the cognitive level 
of the person.
Persons with spasticity limited primarily to muscle groups 
in one limb are excellent candidates for neuromuscular 
blockade with botulinum toxin, phenol or a combination 
of the two. In patients with selective motor control, we are 
more aggressive, with repeat injections accompanied by 
physical therapy, bracing, electrical stimulation, and other 
supportive modalities. Injections should be continued on a 
regular basis at three to four times per year.33 Unsuccessful 
trials should lead to pursuing treatments similar to those for 
generalized spasticity. People commonly encountered in this 
group include individuals afflicted by stroke and hemiplegic 
or diplegic cerebral palsy. Neuromuscular blockade can 
be utilized as an adjunctive therapy, alongside intrathecal 
baclofen therapy, SDR, and musculoskeletal surgery.
Treating generalized spasticity is more complex. Oral 
medication is commonly used as an initial form of treatment. 
However, due to commonly encountered sedation, this can be 
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counterproductive for participation in physical, occupational, 
and speech therapies, as well as for cognitive development. 
For people with severe impairments, demonstrating an 
absence of cognitive development, the level of sedation that 
often accompanies oral medications may be acceptable and/or 
desirable. This scenario is commonly encountered in spastic 
quadriparetic CP and TBI. Care must be exercised following 
TBI, as sedation may mask cognitive recovery.
ITB therapy is considered in individuals with general-
ized spasticity, with intact or developing cognition, and/or 
who fail oral medications.36 While the use of ITB therapy to 
treat spasticity is becoming more commonly practiced, it is 
often overlooked. ITB therapy has been the most universally 
studied option for the treatment of spasticity related to CP. 
Less research has been done to indicate ITB’s significance 
for people with other underlying injuries and diseases of 
the CNS, such as CVA, TBI, MS, and SCI. For example, an 
estimated 17%–42.6% of CVA survivors experience spas-
ticity, but less than 1% of those who experience a disabling 
form of spasticity receive ITB treatment.37 The original 
labeling of baclofen suggested waiting one year after SCI, 
and 6 months following CVA. Our anecdotal experience is 
that earlier treatment may avoid many of the musculoskeletal 
complications of spasticity. This has been demonstrated (in 
the orthopedic literature) in patients with cerebral palsy.38 
Ongoing trials are underway to help clarify this issue. This 
therapy can be considered in growing, and adult, patients with 
di-, hemi- or quadriparetic CP, TBI, MS, or SCI, regardless 
of cognitive status.
Nonpharmacological treatments are important adjuncts 
when treating spasticity, whether it is generalized or focal 
(Figure 2). Nonpharmacological approaches include occu-
pational therapy, physiotherapy, orthotics, casting, or a 
combination of these methods. Strength training is imperative 
to help restore muscle balance. Muscle balance allows nor-
mal muscle, bone, and joint development and maintenance. 
Achieving strength is a key component in reaching normal 
function. There are many variables responsible for restoring 
muscle balance beyond the physiologic ability of muscle to 
be strengthened. This is one of the more critical areas where 
the IDAHO criteria can be useful in assessing the optimal 
delivery of care.
Pediatric considerations
While CVA is the most common cause of spasticity in adults, 
the most common causes in children are CP, TBI, and spinal 
cord injury.39 There is a substantial difference in the impact of 
spasticity on children, versus adults. In adults who experience 
spasticity, inherent muscle length is present, and there is 
no deficiency in normal muscle length and architecture. 
The effects of spasticity in children can be substantially 
more devastating, due to the effects of muscle tightness on 
the growing musculoskeletal system. Unlike bone, muscle 
does not have a growth plate. Muscle growth is directed by 
the tensile forces of the bone, pulling under physiological 
loading as the bone elongates, which subsequently causes 
relaxed muscles to stretch.28 Therefore, muscle grows at 
the rate of bone growth. Children with CP are musculoskel-
etally normal at birth, with spasticity occurring during rapid 
growth, preventing normal bone and muscle development.40 
This muscle shortening can be substantial. In a comparative 
study, longitudinal muscle growth was reduced by 45% in 
spastic mice, compared with normal mice.41 This restricted 
longitudinal muscle growth and increased tension of the 
muscle can result in limb deformities, joint dislocations, and 
poor motor function.42
There are many factors to consider when treating children 
with spasticity. A study by Gorter et al found that spasticity 
is only marginally related to gross motor function develop-
ment in infants of less than 2 years of age who have CP, 
and that other environmental or family factors may have a 
much greater influence on gross motor function.42–44 Here, 
again, it is important to account for factors other than direct 
interventions, in considerations of functional gains. We know 
that severe spasticity often inhibits motor activity, and that 
treating this spasticity may promote development of motor 
pathways, by allowing more movements.39 By aggressively 
treating spasticity early, we may be preserving opportunity 
for future gains.
Despite considerable costs, treating spasticity in children 
has shown to be both cost-effective and beneficial.45 
Repeated intramuscular
injections 
Focal spasticity
Botulinum toxin trial
injection 
Generalized treatment
Negative selective motor 
control
Positive selective motor 
control
Intrathecal baclofen Oral baclofen
Generalized spasticity
Absence of cognitive 
function
Presence of cognitive 
function
Figure 2 Treatment practice in focal and generalized spasticity.
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A study performed by Kan et al compared preoperative 
and postoperative data, using MAS and GMFCS, for two 
groups of children who received either ITB pumps or SDR. 
The results 1 year post-treatment were decreased tone, 
increased range of motion, and improved function, for both 
ITB and SDR groups, showing both surgical treatments to be 
efficacious for children with moderate to severe spasticity. 
The benefits of these successful treatments continue. There 
was a significant decrease in the number of subsequent 
orthopedic procedures needed, and a parents’ satisfaction 
rate of 95.8% with these treatments.1 Having an improved 
range of motion and function not only improves quality of 
life for the child, but also eases the burden of the parents in 
providing proper care.
It has been observed that early treatment of spasticity 
reduces the need for orthopedic surgery for contracture or 
torsion deformity in children with severe spasticity from 
CP.42,45 Eliminating tone allows children to strengthen 
and achieve motor control, thereby preventing the 
musculoskeletal ramifications of spasticity. Evaluating 
functional improvement can be challenging. Though a 
child may be improving, he or she may also be moving 
away from the normal trajectory. For example, children 
with diplegic CP generally experience improvements until 
they reach age six, at which point function often plateaus 
or declines. Up until this time, spasticity can substitute for 
underlying weakness. However, as they mature skeletally 
and gain weight, spasticity becomes a poor surrogate for 
normal muscular balance and strength. This can be explained 
by a power (strength) to weight ratio; young children have 
a high power to weight ratio. However, as children age, 
their mass begins to increase more rapidly in proportion 
to their physical strength, resulting in a reversal: to a low 
power to weight ratio. We must be diligent in avoiding the 
preservation of spasticity for this deceptive “function,” while 
it impairs normal musculoskeletal development.
Conclusion
It is well-established that oral, intramuscular, and intrathe-
cal medications are effective in decreasing spasticity. The 
management of severe spasticity in order to improve function, 
however, involves a complex web of intervening variables, 
including infrastructure, desire and motivation to make life-
style changes, ability remaining following injury, hospital 
access to appropriate care, and opportunity. Spasticity is the 
critical impediment that must be removed for individuals 
striving to reach higher function, or to improve the care and 
comfort of those with severe cognitive impairment.
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